Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 d228097dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress IST achieved U.S.
EX-99.1 2 d228097dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress IST achieved U.S. net product sales of $36.6 million in the second quarter, representing 26% year-over-year growth Royalties portfolio generated $59.8 million in second quarter revenue Launch of wholly-owned Strategic Healthcare Asset, Nortiva Bio, focused on novel extended-release drug delivery technology BURLINGAME, Calif. – Aug 5, 2026 – Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2026, and highlighted select corpor...
Source
Exhibit EX-99.1
0001193125-26-335192
Filed August 5, 2026 at 8:19 PM UTC. The figures above are from the audited statements, not from this release.